Skip Nav Destination
Issues
15 November 2016
-
Cover Image
Cover Image
The cover shows immunohistochemical staining of tumor-associated lymphocytes in a tumor biopsy of a nivolumab-treated patient with mRCC. Immunohistochemical staining shows enrichment in CD3+ (brown) and a modest enrichment in CD4+ (purple) cells at cycle 2, day 8 of nivolumab treatment relative to baseline (not shown). FoxP3 (nuclei, red) stain is also included. For details, see the article by Choueiri and colleagues on page 5461 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Molecular Pathways
Review
Challenges Facing Early Phase Trials Sponsored by the National Cancer Institute: An Analysis of Corrective Action Plans to Improve Accrual
Holly A. Massett; Grace Mishkin; Larry Rubinstein; S. Percy Ivy; Andrea Denicoff; Elizabeth Godwin; Kate DiPiazza; Jennifer Bolognese; James A. Zwiebel; Jeffrey S. Abrams
CCR Focus
Cancer Therapy: Clinical
Author Choice
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Toni K. Choueiri; Mayer N. Fishman; Bernard Escudier; David F. McDermott; Charles G. Drake; Harriet Kluger; Walter M. Stadler; Jose Luis Perez-Gracia; Douglas G. McNeel; Brendan Curti; Michael R. Harrison; Elizabeth R. Plimack; Leonard Appleman; Lawrence Fong; Laurence Albiges; Lewis Cohen; Tina C. Young; Scott D. Chasalow; Petra Ross-Macdonald; Shivani Srivastava; Maria Jure-Kunkel; John F. Kurland; Jason S. Simon; Mario Sznol
The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects
Aaron S. Mansfield; on behalf of the NCI Organ Dysfunction Working Group; Michelle A. Rudek; on behalf of the NCI Organ Dysfunction Working Group; Diana Vulih; on behalf of the NCI Organ Dysfunction Working Group; Gary L. Smith; on behalf of the NCI Organ Dysfunction Working Group; Pamela Jo Harris; on behalf of the NCI Organ Dysfunction Working Group; S. Percy Ivy; on behalf of the NCI Organ Dysfunction Working Group
Personalized Medicine and Imaging
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Benjamin Weide; Alexander Martens; Jessica C. Hassel; Carola Berking; Michael A. Postow; Kees Bisschop; Ester Simeone; Johanna Mangana; Bastian Schilling; Anna Maria Di Giacomo; Nicole Brenner; Katharina Kähler; Lucie Heinzerling; Ralf Gutzmer; Armin Bender; Christoffer Gebhardt; Emanuela Romano; Friedegund Meier; Peter Martus; Michele Maio; Christian Blank; Dirk Schadendorf; Reinhard Dummer; Paolo A. Ascierto; Geke Hospers; Claus Garbe; Jedd D. Wolchok
Noninvasive Detection of Metastases and Follicle Density in Ovarian Tissue Using Full-Field Optical Coherence Tomography
Inge T.A. Peters; Paulien L. Stegehuis; Ronald Peek; Florine L. Boer; Erik W. van Zwet; Jeroen Eggermont; Johan R. Westphal; Peter J.K. Kuppen; J. Baptist Trimbos; Carina G.J.M. Hilders; Boudewijn P.F. Lelieveldt; Cornelis J.H. van de Velde; Tjalling Bosse; Jouke Dijkstra; Alexander L. Vahrmeijer
Cancer Therapy: Preclinical
Author Choice
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
Sen Zhang; Rana Anjum; Rachel Squillace; Sara Nadworny; Tianjun Zhou; Jeff Keats; Yaoyu Ning; Scott D. Wardwell; David Miller; Youngchul Song; Lindsey Eichinger; Lauren Moran; Wei-Sheng Huang; Shuangying Liu; Dong Zou; Yihan Wang; Qurish Mohemmad; Hyun Gyung Jang; Emily Ye; Narayana Narasimhan; Frank Wang; Juan Miret; Xiaotian Zhu; Tim Clackson; David Dalgarno; William C. Shakespeare; Victor M. Rivera
The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer
Richard J. Rebello; Eric Kusnadi; Donald P. Cameron; Helen B. Pearson; Analia Lesmana; Jennifer R. Devlin; Denis Drygin; Ashlee K. Clark; Laura Porter; John Pedersen; Shahneen Sandhu; Gail P. Risbridger; Richard B. Pearson; Ross D. Hannan; Luc Furic
Biology of Human Tumors
Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma
Laurence Feldmeyer; Courtney W. Hudgens; Genevieve Ray-Lyons; Priyadharsini Nagarajan; Phyu P. Aung; Jonathan L. Curry; Carlos A. Torres-Cabala; Barbara Mino; Jaime Rodriguez-Canales; Alexandre Reuben; Pei-Ling Chen; Jennifer S. Ko; Steven D. Billings; Roland L. Bassett; Ignacio I. Wistuba; Zachary A. Cooper; Victor G. Prieto; Jennifer A. Wargo; Michael T. Tetzlaff
Author Choice
Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma
Mathieu Chicard; Sandrine Boyault; Leo Colmet Daage; Wilfrid Richer; David Gentien; Gaelle Pierron; Eve Lapouble; Angela Bellini; Nathalie Clement; Isabelle Iacono; Stéphanie Bréjon; Marjorie Carrere; Cécile Reyes; Toby Hocking; Virginie Bernard; Michel Peuchmaur; Nadège Corradini; Cécile Faure-Conter; Carole Coze; Dominique Plantaz; Anne Sophie Defachelles; Estelle Thebaud; Marion Gambart; Frédéric Millot; Dominique Valteau-Couanet; Jean Michon; Alain Puisieux; Olivier Delattre; Valérie Combaret; Gudrun Schleiermacher
Human Microbiome Fusobacterium Nucleatum in Esophageal Cancer Tissue Is Associated with Prognosis
Kensuke Yamamura; Yoshifumi Baba; Shigeki Nakagawa; Kosuke Mima; Keisuke Miyake; Kenichi Nakamura; Hiroshi Sawayama; Koichi Kinoshita; Takatsugu Ishimoto; Masaaki Iwatsuki; Yasuo Sakamoto; Yoichi Yamashita; Naoya Yoshida; Masayuki Watanabe; Hideo Baba
Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group
Ariadne H.A.G. Ooms; Samantha Gadd; Daniela S. Gerhard; Malcolm A. Smith; Jaime M. Guidry Auvil; Daoud Meerzaman; Qing-Rong Chen; Chih Hao Hsu; Chunhua Yan; Cu Nguyen; Ying Hu; Yussanne Ma; Zusheng Zong; Andrew J. Mungall; Richard A. Moore; Marco A. Marra; Vicki Huff; Jeffrey S. Dome; Yueh-Yun Chi; Jing Tian; James I. Geller; Charles G. Mullighan; Jing Ma; David A. Wheeler; Oliver A. Hampton; Amy L. Walz; Marry M. van den Heuvel-Eibrink; Ronald R. de Krijger; Nicole Ross; Julie M. Gastier-Foster; Elizabeth J. Perlman
Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry–Based Phosphotyrosine Proteomics
Scott M. Haake; Jiannong Li; Yun Bai; Fumi Kinose; Bin Fang; Eric A. Welsh; Roy Zent; Jasreman Dhillon; Julio M. Pow-Sang; Y. Ann Chen; John M. Koomen; W. Kimryn Rathmell; Mayer Fishman; Eric B. Haura
Letter to the Editor
Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials—Letter
Mogens Groenvold; Neil K. Aaronson; Anne-Sophie E. Darlington; Deborah Fitzsimmons; Eva Greimel; Bernhard Holzner; Jaap C. Reijneveld; Krzysztof A. Tomaszewski; Irma Verdonck-de Leeuw; Lonneke van de Poll-Franse; on behalf of the EORTC Quality of Life Group
Correction
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds